A Phase IB Trial of Autologous Cytokine‐Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death‐1, plus Chemotherapy in Patients with Advanced Non‐Small‐Cell Lung Cancer-Reference-Cited by-同舟云学术

A Phase IB Trial of Autologous Cytokine‐Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death‐1, plus Chemotherapy in Patients with Advanced Non‐Small‐Cell Lung Cancer

Published:2022-12 Issue:8 Volume:23 Page:709-719
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Zhou Li,Xiong Yanjuan,Wang Yang,Meng Yuan,Zhang Weihong,Shen Meng,Zhang Xinwei,Li Shuzhan,Ren Baozhu,Li Runmei,Han Ying,Zhang Jiali,Cao Shui,Du Weijiao,Sun Qian,Wei Feng,An Xiumei,Yang Lili,Zhang Yuwei,Ma Wenchao,Xu Wengui,Zhang Yi,Jiang Jingting,Xu Xiang,Xia Jianchuan,Liu Liang,Ren Xiubao^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer;Carbone;N Engl J Med,2017

3. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

4. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer;Paz-Ares;N Engl J Med,2018

5. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial;West;Lancet Oncol,2019

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Sintilimab Plus Radiotherapy on Levels of Spondin-2 and Glucose Transporter-1 in Patients with Cervical Cancer;International Journal of General Medicine;2024-07

2. New insights into immune cells in cancer immunotherapy: from epigenetic modification, metabolic modulation to cell communication;MedComm;2024-05-23

3. Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer;Molecular Cancer;2024-04-24

4. Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy;Cancer Immunology, Immunotherapy;2024-01-27

5. Enhanced tumor control activities of anti-mPD-L1 antibody and antigen-presenting cell-like natural killer cell in an allograft model;BMC Cancer;2024-01-26